According to a research report compiled by Fact.MR, the global cancer profiling market is expected to witness robust growth, registering a CAGR of 17.7% during the forecast period 2017-2026. By the end of 2026, the global cancer profiling market is estimated to reach a revenue of US$ 12,212,960 million. The use of cancer profiling is increasing as the incidence of new cancer cases increases.
According to the National Cancer Institute, new cancer cases are expected to reach 22 million within the next two years. Additionally, increasing adoption of precision medicine treatments is driving the demand for cancer profiling. Here are some insights on how the global cancer profiling market will perform in the coming years.
Download sample copy of this report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=358?AS
Forecast highlights for the global cancer profiling market
1- North America is expected to maintain its dominant position in the global cancer profiling market during the forecast period 2017-2026. Cancer patients are increasing due to changes in lifestyle, drinking, and smoking. Additionally, increasing investment in research and development activities is driving the demand for cancer profiling in the region.
2- Asia Pacific Excluding Japan (APEJ) and Europe are also seeing significant growth in cancer profiling. The increasing incidence of lung and prostate cancer in Central, Eastern and Southern Europe is driving the demand for cancer profiling. Meanwhile, breast cancer is the most frequently diagnosed cancer among Chinese and Indian women. 3- Next-generation sequencing is expected to become the most preferred technology in the cancer profiling market. By the end of 2026, next-generation sequencing is estimated to reach 62 billion revenues.
4- Pharmaceutical and biotechnology companies are expected to be the largest users of cancer profiling. Pharmaceutical and biotech companies are estimated to surpass $52.4 billion in revenue by the end of 2026.
5- Diagnostics is expected to witness significant growth in the global cancer profiling market. By the end of 2026, diagnostics revenue is estimated to exceed $40 billion.
competitive landscape
These aforementioned players rely on a variety of organic and inorganic growth strategies to strengthen their market presence. Offering new products, building strategic alliances, acquiring and merging with other players, and conducting clinical trials to determine drug efficacy are just a few examples.
- For example, F. Hoffmann La Roche Ltd. updated its phase 3 IMbrave 150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacicumab) compared to sorafenib in patients with unresectable hepatocellular carcinoma. Published overall survival (OS) data. (HCC) Those who have not received prior systemic therapy.
- In January 2021, Illumina Inc. announced a series of new and expanded oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics and Merck to advance comprehensive genomic profiling. This partnership is an extension of the TruSightTM Oncology 500 (TSO 500) Research Use Only comprehensive pan-cancer test to profile known and emerging tumors.
- Recently, in February 2021, QIAGEN NV collaborated with INOVIO to develop VGX-3100’s next-generation sequencing (NGS) companion diagnostic for the treatment of cervical dysplasia. Initial projects of this extended collaboration will focus on joint development of a diagnostic test to identify women most likely to benefit from clinical use of VGX-3100.
market titan
- F. Hoffmann LaRoche Ltd.
- Illumina Co., Ltd.
- Qiagen
- Thermo Fisher Scientific Inc.
- Abbott
- Nanostring Technologies
- Siemens AG
- HTG Molecular Diagnostics, Inc.
- Perkin Elmer Inc.
- Agilent Technologies
- Negenomics Lab Inc.
- genomic health
- Biogenex
- California Inc.의 Pacific Biosciences
market structure
- product
instrumentImmunohistochemistry (IHC) analyzer
FISH(Fluorescence in-situ Hybridization) 기기
PCR instrument
DNA sequencer
fragment analyzer
Expendablesreagents and kits
Other auxiliary devices (probes, holders, etc.) - markbreast cancer
colorectal cancer
ovarian cancer
melanoma
kidney cancer
Lung cancer (including NSCLC)
rare cancer - end userhospital
diagnostic center
cancer research institute
etc - testImmunohistochemistry (IHC)
FISH(Fluorescence in-situ Hybridization)
Qualitative polymerase chain reaction (qPCR)
Next-generation sequencing (NGS)
Sanger test
fragment analysis - regionNorth America
Latin America
europe
CIS and Russia
japan
appeal
thing
Key Questions Addressed by the Cancer Profiling Report
- What is the projected value of cancer profiling in 2023?
- How much will global cancer profiling increase by 2033?
- What are the factors driving the growth of cancer profiling?
- Which regions are projected to lead in global cancer profiling between 2023 and 2033?
- What are the factors driving cancer profiling during the forecast period?
- What will be the estimated market value of cancer profiling during the forecast period?